281-296-7300

  • Awards
  • Careers
logo
  • About
    • About VGXI
    • Leadership
    • VGXI Mission
    • Awards
    • Careers
  • Services
    • Manufacturing Services
    • cGMP Plasmid
    • HD Plasmid
    • Pre-Clinical Plasmid
    • Additional Services
  • VGXI Process
    • VGXI Manufacturing Process
    • Analytical Testing
    • Quality Systems
  • Resource Center
    • News
    • Events
    • FAQs
    • Whitepapers
    • Posters & Presentations
  • Contact Us
  • Awards
  • Careers

Recent News

VGXI Official Statement Regarding COVID-19

March 19, 2021

A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED March 19, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »

VGXI to Manufacture Vaccine Against Novel Coronavirus Under CEPI Funded Collaboration

January 29, 2020

Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV)… Read More »

VGXI, Inc. Establishes Pilot mRNA Manufacturing Capabilities

December 6, 2019

Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines. The Woodlands, TX – VGXI announces successful implementation of new RNA production services through completion of all Phase II initiatives as part of a… Read More »

VGXI Selects BE&K as Design-Build Partner for New Manufacturing Facility

December 3, 2019

Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility December 3, 2019, The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services… Read More »

VGXI to Exhibit at the Annual ISV Congress

October 7, 2019

The ISV Annual Congress is the world’s largest scientific conference in the field of vaccines and covers a broad range of topics related to vaccines and immunotherapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing… Read More »

VGXI to Exhibit at the International HCV Symposium

September 17, 2019

The 26th International Symposium on Hepatitis C Virus and Related Viruses focuses on the advancement of HCV and related virus research, vaccines, and therapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing services and experience!… Read More »

VGXI to Exhibit at the Cell & Gene Meeting on the Mesa

September 17, 2019

The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Be sure to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn how VGXI’s… Read More »

Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT-EPIC-Based Personalized Cancer Therapeutics

June 22, 2019

Industry recognized plasmid DNA manufacturer VGXI, Inc. to support production of personalized cancer therapies as part of a long-term supply agreement with Geneos Therapeutics. June 22, 2019, The Woodlands, TX and Plymouth Meeting, PA – Plasmid CMO VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals (NASDAQ: INO) focused on developing… Read More »

VGXI Announces Launch of its New Website

May 20, 2019

A new and completely redesigned website offers visitors a comprehensive overview of VGXI’s range of plasmid DNA manufacturing services and capabilities. May 20, 2019, The Woodlands, TX – Texas based CMO VGXI, Inc., which specializes in production of DNA plasmid biopharmaceuticals, announced it has gone live with a refreshed website and online… Read More »

VGXI to Exhibit at the 2019 BIO International Convention

May 6, 2019

With over 16,000 attendees, BIO is one of the largest biotech partnering, education, and networking events in the world. Be sure to stop by VGXI’s Booth #3349 or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services can support your gene or cell therapy program! Contact Us directly… Read More »

VGXI Announces Participation in the 2019 ASGCT Annual Meeting

April 4, 2019

Plasmid CMO VGXI will be speaking at the 22nd Annual ASGCT Meeting in Washington DC. April 04, 2019, The Woodlands, TX – VGXI, Inc., an industry leading plasmid DNA contract manufacturing organization today announced that Mr. Stephen Rodriguez, Sr. Manager, Process Development, will be presenting during the Tools and Technologies Forum of… Read More »

Meet with VGXI at the 2019 ASGCT Meeting

April 3, 2019

The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. Visit VGXI’s Booth #411 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene or… Read More »

VGXI Announces Continued Progress for RNA Manufacturing Partnership

March 15, 2019

Texas based CMO VGXI Announces Completion of Initial Tech Transfer Milestones as part of its Partnership Agreement for Production of RNA Therapeutics with HMRI. March 15, 2019, The Woodlands, TX – Under a license agreement with the Houston Methodist Research Institute (HMRI) for development of clinical grade RNA manufacturing services, VGXI announced… Read More »

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 17
  • Next »

Archives

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • About
  • Services
  • VGXI Process
  • Contact Us
  • Careers
  • Awards
  • Resource Center
logo white

281-296-7300
2700 Research Forest Drive, Suite 180
The Woodlands, Texas 77381, USA

Please enter your name.
Please enter a valid email address.
Sign Up

Thanks for subscribing! Please check your email for further instructions.

Something went wrong. Please check your entries and try again.

© 2021 VGXI, Inc. All Rights Reserved.Terms | Privacy Policy

The VGXI Website is set to allow the use of cookies. Cookies help us to give you the best experience on our website. By clicking Accept or continuing to use the site, you agree to use our cookies. If you decline we will not track your information but your browsing experience might be limited. Please visit our Terms and Conditions and our Privacy Policy for more information.AcceptDecline